BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35074299)

  • 1. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
    Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of renal phospholipase A2 receptor deposit in the prognosis evaluation and treatment options of idiopathic membranous nephropathy: A retrospective cohort study.
    Xie Z; Dong W; Li Z; Chen Y; Song L; Li R; Wu Y; Fu L; Liang H; Tao Y; Xie J; Wang W; Liu S; Ye Z; Shi W; Liang X
    Nephrology (Carlton); 2020 Mar; 25(3):219-229. PubMed ID: 31900967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A novel approach to rapid induction of remission in primary membranous nephropathy].
    Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
    Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
    Li C; Li H; Wen YB; Li XM; Li XW
    BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy].
    Tan T; Zheng Y; Li Y; Zeng Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):1047-1050. PubMed ID: 37439180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
    Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
    [No Abstract]   [Full Text] [Related]  

  • 17. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.
    Glassock RJ
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1341-3. PubMed ID: 25035274
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
    Chen M; Zhang X; Xiong Y; Xu G
    Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.